ArticleClinical and experimental medicine2026
Exploratory study of PD-1 inhibitors with or without ruxolitinib for the treatment of adult EBV-associated hemophagocytic lymphohistiocytosis: a real-world data-based preliminary investigation.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To preliminarily analyze the clinical efficacy and safety of PD-1 inhibitors as monotherapy or in combination with ruxolitinib (RUX) for adult Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) based on real-world retrospective data. A retrospective case series analysis was performed on clinical data of 4 adult EBV-HLH patients treated with sintilimab (a PD-1 inhibitor) alone or combined with RUX at the Department of Hematology, Hunan Provincial People’s Hospital, from April 1, 2020 to February 1, 2024. Clinical efficacy, survival outcomes, dynamic changes of laboratory indicators and adverse reactions were observed. Among the 4 patients, 2 achieved complete remission (CR), 1 experienced treatment interruption due to non-adherence and was lost to follow-up, and 1 died of multi-organ failure induced by COVID-19, with a 1-year overall survival (OS) rate of 75.00%. All patients received sintilimab with a median treatment course of 9.5 cycles and a median infusion dose of 1900 mg; 3 patients were combined with RUX. After one cycle of treatment, the levels of alanine aminotransferase (ALT), aspartate transaminase (AST) and interleukin-10 (IL-10) decreased significantly, while white blood cell (WBC), hemoglobin (HGB) and platelet (PLT) levels increased significantly (all P < 0.05). Ferritin (Ferr) returned to the normal range and fibrinogen (Fbg) showed an upward trend. The number of peripheral blood T, B and natural killer (NK) cells increased in 3 patients who completed lymphocyte subset detection. No drug-related severe adverse reactions of grade 3 or above were observed in all patients. PD-1 inhibitors alone or combined with RUX show preliminary favorable efficacy and high tolerability in the treatment of adult EBV-HLH, which can effectively improve blood cell levels, control inflammatory responses and increase clinical remission rates. However, large-sample prospective studies are required to verify the long-term efficacy due to the small sample size of this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.